Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment
There are limited data available about the durability of the immune response after administration of the widely used adenovirus-vectored ChAdOx1-nCoV-19 vaccine in cancer patients. This prospective longitudinal observational study analyzed follow-up data of immunogenic responses 12 weeks after the s...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/10/1662 |
| _version_ | 1797469719470538752 |
|---|---|
| author | Passakorn Wanchaijiraboon Nattaya Teeyapun Nussara Pakvisal Panot Sainamthip Thiti Susiriwatananont Nicha Zungsontiporn Nungruthai Suntronwong Preeyaporn Vichaiwattana Worata Klinsawat Nasamon Wanlapakorn Suebpong Tanasanvimon Virote Sriuranpong Yong Poovorawan Sutima Luangdilok |
| author_facet | Passakorn Wanchaijiraboon Nattaya Teeyapun Nussara Pakvisal Panot Sainamthip Thiti Susiriwatananont Nicha Zungsontiporn Nungruthai Suntronwong Preeyaporn Vichaiwattana Worata Klinsawat Nasamon Wanlapakorn Suebpong Tanasanvimon Virote Sriuranpong Yong Poovorawan Sutima Luangdilok |
| author_sort | Passakorn Wanchaijiraboon |
| collection | DOAJ |
| description | There are limited data available about the durability of the immune response after administration of the widely used adenovirus-vectored ChAdOx1-nCoV-19 vaccine in cancer patients. This prospective longitudinal observational study analyzed follow-up data of immunogenic responses 12 weeks after the second dose of the ChAdOx1-nCoV-19 vaccine in 290 oncological patients compared to healthy controls. The study aimed to assess the persistence of the humoral immune response three months after the second dose, and omicron neutralization was also evaluated. Three months after completion of the second vaccine dose, the geometric mean titer of SARS-CoV-2 binding total Ig statistically decreased by 42% compared to those at 4 weeks, and was lower than that of the healthy control. Six percent of patients became seronegative for anti-RBD total Ig. Only 5% (2 of 40 samples) tested positive for surrogate neutralization against SAR-CoV-2 Omicron BA.2. Across different therapy types, a waning in immunogenicity was observed within three months after the second dose of the ChAdOx1 nCoV-19 vaccine, rendering it insufficient at that point to protect against the SAR-CoV-2 Omicron BA.2 variant. |
| first_indexed | 2024-03-09T19:25:12Z |
| format | Article |
| id | doaj.art-bcf02b0081da41388d16e97573166523 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T19:25:12Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-bcf02b0081da41388d16e975731665232023-11-24T03:03:53ZengMDPI AGVaccines2076-393X2022-10-011010166210.3390/vaccines10101662Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer TreatmentPassakorn Wanchaijiraboon0Nattaya Teeyapun1Nussara Pakvisal2Panot Sainamthip3Thiti Susiriwatananont4Nicha Zungsontiporn5Nungruthai Suntronwong6Preeyaporn Vichaiwattana7Worata Klinsawat8Nasamon Wanlapakorn9Suebpong Tanasanvimon10Virote Sriuranpong11Yong Poovorawan12Sutima Luangdilok13Phrapokklao Cancer Center of Excellence, Phrapokklao Clinical Research Center, Phrapokklao Genomic Laboratories, Phrapokklao Hospital, Mueang District, Chanthaburi 22000, ThailandThe King Chulalongkorn Memorial Hospital, Bangkok 10330, ThailandThe King Chulalongkorn Memorial Hospital, Bangkok 10330, ThailandDepartment of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandThe King Chulalongkorn Memorial Hospital, Bangkok 10330, ThailandThe King Chulalongkorn Memorial Hospital, Bangkok 10330, ThailandCenter of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok 10330, ThailandCenter of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok 10330, ThailandConservation Ecology Program, School of Bioresources and Technology, King Mongkut’s University of Technology, Bangkok 10150, ThailandCenter of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok 10330, ThailandDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandDivision of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandCenter of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and The King Chulalongkorn Memorial Hospital, Bangkok 10330, ThailandDepartment of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandThere are limited data available about the durability of the immune response after administration of the widely used adenovirus-vectored ChAdOx1-nCoV-19 vaccine in cancer patients. This prospective longitudinal observational study analyzed follow-up data of immunogenic responses 12 weeks after the second dose of the ChAdOx1-nCoV-19 vaccine in 290 oncological patients compared to healthy controls. The study aimed to assess the persistence of the humoral immune response three months after the second dose, and omicron neutralization was also evaluated. Three months after completion of the second vaccine dose, the geometric mean titer of SARS-CoV-2 binding total Ig statistically decreased by 42% compared to those at 4 weeks, and was lower than that of the healthy control. Six percent of patients became seronegative for anti-RBD total Ig. Only 5% (2 of 40 samples) tested positive for surrogate neutralization against SAR-CoV-2 Omicron BA.2. Across different therapy types, a waning in immunogenicity was observed within three months after the second dose of the ChAdOx1 nCoV-19 vaccine, rendering it insufficient at that point to protect against the SAR-CoV-2 Omicron BA.2 variant.https://www.mdpi.com/2076-393X/10/10/1662COVID-19 vaccineOmicronChAdOx1cancerimmunogenicitySARS-CoV-2 |
| spellingShingle | Passakorn Wanchaijiraboon Nattaya Teeyapun Nussara Pakvisal Panot Sainamthip Thiti Susiriwatananont Nicha Zungsontiporn Nungruthai Suntronwong Preeyaporn Vichaiwattana Worata Klinsawat Nasamon Wanlapakorn Suebpong Tanasanvimon Virote Sriuranpong Yong Poovorawan Sutima Luangdilok Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment Vaccines COVID-19 vaccine Omicron ChAdOx1 cancer immunogenicity SARS-CoV-2 |
| title | Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment |
| title_full | Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment |
| title_fullStr | Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment |
| title_full_unstemmed | Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment |
| title_short | Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment |
| title_sort | durability of immune response to chadox1 ncov 19 vaccine in solid cancer patients undergoing anticancer treatment |
| topic | COVID-19 vaccine Omicron ChAdOx1 cancer immunogenicity SARS-CoV-2 |
| url | https://www.mdpi.com/2076-393X/10/10/1662 |
| work_keys_str_mv | AT passakornwanchaijiraboon durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT nattayateeyapun durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT nussarapakvisal durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT panotsainamthip durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT thitisusiriwatananont durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT nichazungsontiporn durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT nungruthaisuntronwong durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT preeyapornvichaiwattana durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT worataklinsawat durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT nasamonwanlapakorn durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT suebpongtanasanvimon durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT virotesriuranpong durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT yongpoovorawan durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment AT sutimaluangdilok durabilityofimmuneresponsetochadox1ncov19vaccineinsolidcancerpatientsundergoinganticancertreatment |